Bayer is studying an investigational drug, Vilaprasin, in women who have been diagnosed with uterine fibroids vs standard treatment.
This study will compare 0.1mg and 0.05mg of spinal morphine for postoperative pain after scheduled, elective Cesarean delivery. All patients will receive a spinal anesthetic (single injection in the lower back to numb patients from the waist down) for operative anesthesia and will be
randomized into one of two groups: (group 1) 0.1mg spinal morphine and (group 2) 0.05mg spinal morphine. This will be a randomized, single blinded study.
The purpose of this study is to look at the long term effects and safety of Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids, who have already participated in the first study M12-815. Subjects will currently be enrolled in the first study.
This study is try to understand current patients with fibroids and there choices for management. We will follow women through their journey and obtain patient reported outcomes, through questionnaire's, following their current therapies for Uterine Fibroids, including symptoms, quality of life, work productivity impact, and satisfaction.
The purpose of this study is to evaluate the safety and benefits of treating mild chronic hypertension (CHTN), or high blood pressure, with medication during pregnancy vs non treatment. Medication prescribed is medication currently approved to treat severe CHTN.
The purpose of this study is to validate a test developed to determine preterm labor, to determine the optimal time to preform the test, and to discover biomarkers that will date a pregnancy and predict the time to birth.
The purpose of this study is to study an alternative to unopposed estrogen in premenopausal women that have endometriosis-related pain at the time of hysterectomy (removal of the womb). We will compare a type of estrogen alone with another combination medication that has the same type of estrgrogen plus another medication called bazodoxiphene (Duavee). We will compare the effect of Duavee with estrogen alone on endometriosis-associated pain scores after 6 months of therapy.
Long-acting reversible contraceptive (LARC) services (including the contraceptive implant and intrauterine devices, or IUDs) are the most effective forms of reversible contraception. The immediate postpartum period (inpatient), prior to discharge from the hospital, can be a particularly favorable period to initiate a contraceptive method, reducing the risk of unintended pregnancy as many women resume sexual activity before their postpartum check-up or do not attend this checkup. Women who are pregnant and ineligible for Medicaid and without access to other forms of insurance are eligible to apply for Emergency Medicaid to cover the cost of hospital-based labor and delivery. Currently, Emergency Medicaid does not cover the costs of inpatient postpartum LARCs (or any other form of contraception). South Carolina Medicaid does cover these services, and the three hospitals participating in this study (Greenville Health System, Palmetto Health Richland, and the Medical University of South Carolina) currently provide inpatient LARC services. We propose to offer women delivering at these three hospitals with Emergency Medicaid coverage no-cost postpartum inpatient LARCs. Before they are discharged from the hospital, we will conduct brief surveys with women to assess their contraceptive choices and reasons; we will also review medical charts to describe prenatal care utilization and receipt of contraceptive counseling. The results of this study will inform discussions with South Carolina's Department of Health and Environmental Control (DHEC) on expanding the scope of Title X Family Planning contracts with hospitals to include inpatient postpartum LARCs so that this population of women has greater access to highly effective contraceptive services and is better able to prevent unintended pregnancies.
The purpose of this study is to test how well patients with heavy menstrual bleeding associated with uterine fibroids respond to a medication called Elagolix. It aims to possibly find out how heavy menstrual bleeding associated with uterine fibroids and related conditions develop and progress and how they can be diagnosed, monitored, or treated, possibly develop tests to identify which patients are likely to have different diseases, respond to the study drug or drugs of the same or similar class, or to predict the progression of the heavy menstrual bleeding associated with uterine fibroids, and to possibly develop new therapies, research methods, or technologies. Participation in the study will last approximately 20 months.
Women who have completed treatment for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer and are cancer free will be randomized to either Group 1 (diet and physical activity intervention group) or Group 2 (the usual diet and physical activity group). Group 1 Intervention will include regularly scheduled lifestyle intervention coaching sessions that will be conducted over the telephone and increased physical activity. Patients will be asked to complete daily lifestyle journal that will track daily fat grams and steps. Group 2 will continue with ususal diet and physical activity and will participate in coaching phone calls. Participants will be asked to complete Patient Questionnaires. If participants consent to optional blood submission study, blood samples for research will be drawn at baseline, 3, 6,12 and 24 months from study entry. Participation will last for 24 months.